SystImmune
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15318 NE 95th St, Redmond, Washington, 9...Phone Number
(425) 453-6841Website
www.systimmune.comRevenue
$7.2 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SystImmune
SystImmune, Inc. is a biopharmaceutical company specializing in the development of innovative bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for cancer treatment. The company aims to create biologics that directly target tumors and activate the immune system to enhance anti-tumor responses. With a multidisciplinary team and advanced technology platforms, SystImmune is committed to delivering transformative therapies to patients worldwide. They are actively seeking partnerships to further develop and commercialize their novel therapeutics.Explore more
SystImmune Org Chart
LE
Senior Director
GK
Senior Director Clinical Contracting
SS
Senior Director, Commercial Strategy
CL
Director, Clinical Project Management
TH
Director
LV
Director, Clinical Project Management
LP
Director, Regulatory Strategy
NM
Director of Clinical Science
SY
Associate Director, Clinical Project Manageme...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SystImmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when SystImmune launches new products
Check if SystImmune has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at SystImmune
Funding: Get notified immidiatlly once SystImmune has new funding data
Check out if SystImmune is spiking on competitors!
Click to see if SystImmune had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
SystImmune, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on SystImmune recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined SystImmune as Masked Content
Find more new buyers
Compare Similar Companies to SystImmune
Compare insights from companies similar to SystImmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SystImmune is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SystImmune is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SystImmune.
SystImmune financials insights
Gather financial insights about SystImmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
SystImmune Tech Stack
A closer look at the technologies used by SystImmune
Most Recent Scoops
Facilities Relocation / Expansion
SystImmune is planning to move offices in September 2026. The move will impact approximately 60 employees at the existing office located at 15318 NE 95th St, Redmond, WA.
Facilities Relocation/Expansion
Person-Based
Pharmaceuticals
Person-Based
Medical Research
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
SystImmune News & Media
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
REDMOND, Wash., July 17, 2026 /PRNewswire/ -- SystImmune Inc. (SystImmune) today announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's National Medical Products Administration (NMPA) for iza-bren (izalontamab...SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
First regulatory approval for iza-bren (BL-B01D1), a first-in-class EGFR×HER3 bispecific antibody-drug conjugate (ADC) Represents an important new treatment option for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed following prior platinum-based...SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
REDMOND, Wash., June 1, 2026 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the oral presentation of Phase 1 data for BL-M14D1 in patients with small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors (BL-M14D1-101,...New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
REDMOND, Wash., May 21, 2026 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan), BL-M14D1, T-Bren (BL-M07D1), and BL-M05D1, four distinct clinical programs from its antibody...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SystImmune
Sign Up For FreeTo access detailed company insights
SystImmune, Inc. is a biopharmaceutical company specializing in the development of innovative bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for cancer treatment. The company aims to create biologics that directly target tumors and activate the immune system to enhance anti-tumor responses. With a multidiscipl... Read More
